莫沙必利联合奥美拉唑镁治疗反流性食管炎患者的临床研究  

Clinical trial of mosapride combined with omeprazole magnesium in the treatment of patients with reflux esophagitis

作　　者：邹会 汪照函[2] 盛景义 方丽娟 黄宽忠 ZOU Hui;WANG Zhao-han;SHENG Jing-yi;FANG Li-juan;HUANG Kuan-zhong(Department of Gastroenterology,Jingdezhen Hospital of Traditional Chinese Medicine,Jingdezhen 333000,Jiangxi Province,China;Department of Gastroenterology,Jiangxi Provincial People's Hospital,Nanchang 330006,Jiangxi Province,China;Department of Gastroenterology,JingdezhenFirst People's Hospital,Jingdezhen 333000,Jiangxi Province,China)

机构地区：[1]景德镇市中医医院消化内科,江西景德镇333000 [2]江西省人民医院消化内科,江西南昌330006 [3]景德镇市第一人民医院消化内科,江西景德镇333000

出　　处：《中国临床药理学杂志》2022年第24期2941-2945,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的 观察莫沙必利联合奥美拉唑镁治疗反流性食管炎、改善患者胃肠激素水平的效果及安全性。方法 将72例反流性食管炎患者随机分为试验组36例和对照组36例。对照组给予艾司奥美拉唑镁肠溶片,每次20 mg,每天2次,口服。试验组在对照组的基础上加用枸橼酸莫沙必利片,每次5 mg,每天3次,口服。2组均治疗2个月,并随访3个月。观察2组患者治疗后的临床疗效,观察治疗前后胃肠激素、血清疾病相关因子水平和治疗期间的药物不良反应发生情况,随访3个月复发情况。结果 治疗后,试验组和对照组的总有效率分别为94.29%和74.29%,差异有统计学意义(P<0.05)。治疗后,试验组和对照组胃泌素(GAS)分别为(96.94±5.92)和(69.22±4.48)pg·mL^(-1);胃动素(MOT)分别为(278.82±21.53)和(179.75±15.45)pg·mL^(-1);血管活性肠肽(VIP)分别为(13.42±1.28)和(23.29±1.25)pg·mL^(-1);胃蛋白酶原Ⅰ(PGⅠ)分别为(131.60±11.17)和(115.06±12.36)μg·L^(-1);胃蛋白酶原Ⅱ(PGⅡ)分别为(14.79±1.88)和(23.97±2.90)μg·L^(-1);降钙素基因相关肽(CGRP)分别为(2.50±0.91)和(4.03±0.62)pg·mL^(-1);瘦素(Leptin)分别为(8.30±1.18)和(16.61±2.95)pg·mL^(-1);生长激素释放肽(Ghrelin)分别为(26.07±3.20)和(18.42±3.80)ng·mL^(-1);氢离子浓度指数(pH)值<4反流次数为(22.50±2.91)和(37.03±3.62)次;反流持续时间>5 min次数为(1.60±0.28)和(2.91±0.25)次;pH值<4总时间为(6.11±1.70)和(9.24±1.91)min。上述指标,2组比较差异均有统计学意义(均P<0.05)。治疗期间试验组发生恶心呕吐1例,头晕2例,皮肤瘙痒1例,皮疹2例,药物不良反应发生率为17.14%;对照组发生恶心呕吐2例,血压升高1例,皮肤瘙痒1例,皮疹1例,药物不良反应发生率为14.28%,差异无统计学意义(P>0.05)。试验组、对照组患者随访3个月复发率分别为3.03%和26.92%,试验组复发率低于对照组(P<0.05)。结论 莫沙必利联合奥美拉唑镁治疗反流性食管炎具有较�Objective To observe the efficacy and safety of mosapride combined with omeprazole magnesium in the treatment of reflux esophagitis by improving the gastrointestinal hormone levels in patients.Methods A total of 72 patients with reflux esophagitis were randomly divided into treatment group 36 cases and control group 36 cases.Control group was given omeprazole magnesium enteric-coated tablets,orally,20 mg once,bid,twice a day.Treatment group was given mosapride citrate tablets on the basis of control group,orally,5 mg once,bid,3 times a day.Both groups were treated for 2 months and followed up for 3 months.The efficacy after treatment,the levels of gastrointestinal hormones and serum disease-related factors before and after treatment,and the occurrence of adverse drug reactions during treatment,recurrence rate in the 3 month follow-up were compared between the two groups.Results After treatment,the total effective rates of treatment group and control group were 94.29%and 74.29%,with significant difference (P<0.05).After treatment,the gastrin (GAS)in treatment group and control group were (96.94±5.92) and (69.22±4.48) pg·m L^(-1);the motilin (MOT) were(278.82±21.53) and (179.75±15.45) pg·m L^(-1);vasoactive intestinal peptide (VIP) were (13.42±1.28) and (23.29±1.25) pg·m L^(-1);pepsinogenⅠ(PGⅠ) were (131.60±11.17) and (115.06±12.36)μg·L^(-1);pepsinogenⅡ(PGⅡ) were (14.79±1.88) and (23.97±2.90)μg·L^(-1);calcitonin gene-related peptide(CGRP) were (2.50±0.91) and (4.03±0.62) pg·m L^(-1);Leptin were (8.30±1.18) and (16.61±2.95)pg·m L^(-1);Ghrelin were (26.07±3.20) and (18.42±3.80) ng·m L^(-1);the number of times of reflux at potential of hydrogen (p H) value<4 was (22.50±2.91) and (37.03±3.62) times;the times of reflux duration>5 min was(1.60±0.28) and (2.91±0.25) times;the total time of p H value<4 were (6.11±1.70) and (9.24±1.91)min;there were significant differences in the above indicators between the two groups (all P<0.05).During the treatment period,1 case of nausea and vomi

关 键 词：反流性食管炎 莫沙必利 质子泵抑制药 胃肠激素 疾病相关因子 

分 类 号：R97[医药卫生—药品]